Published in Genes Immun on February 24, 2011
Needles in stacks of needles: finding disease-causal variants in a wealth of genomic data. Nat Rev Genet (2011) 6.52
Gene-based testing of interactions in association studies of quantitative traits. PLoS Genet (2013) 1.23
Genomic analyses with biofilter 2.0: knowledge driven filtering, annotation, and model development. BioData Min (2013) 1.15
Six Degrees of Epistasis: Statistical Network Models for GWAS. Front Genet (2012) 1.04
Analysis pipeline for the epistasis search - statistical versus biological filtering. Front Genet (2014) 0.96
Epistasis and immunity: the role of genetic interactions in autoimmune diseases. Immunology (2012) 0.90
Pathway-guided identification of gene-gene interactions. Ann Hum Genet (2014) 0.83
Novel genes in Human Asthma Based on a Mouse Model of Allergic Airway Inflammation and Human Investigations. Allergy Asthma Immunol Res (2014) 0.83
Biology-Driven Gene-Gene Interaction Analysis of Age-Related Cataract in the eMERGE Network. Genet Epidemiol (2015) 0.83
Gene ontology analysis of pairwise genetic associations in two genome-wide studies of sporadic ALS. BioData Min (2012) 0.82
Th17-related genes and celiac disease susceptibility. PLoS One (2012) 0.82
A PLSPM-based test statistic for detecting gene-gene co-association in genome-wide association study with case-control design. PLoS One (2013) 0.81
Analysis of gene-gene interactions using gene-trait similarity regression. Hum Hered (2014) 0.80
Novel somatic single nucleotide variants within the RNA binding protein hnRNP A1 in multiple sclerosis patients. F1000Res (2014) 0.78
Identifying gene-gene interactions that are highly associated with four quantitative lipid traits across multiple cohorts. Hum Genet (2016) 0.75
Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med (2007) 17.06
Genome-wide strategies for detecting multiple loci that influence complex diseases. Nat Genet (2005) 14.88
Detecting gene-gene interactions that underlie human diseases. Nat Rev Genet (2009) 12.07
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet (2009) 7.16
Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet (2007) 5.09
Pathway analysis of seven common diseases assessed by genome-wide association. Genomics (2008) 4.11
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet (2009) 3.92
Case/pseudocontrol analysis in genetic association studies: A unified framework for detection of genotype and haplotype associations, gene-gene and gene-environment interactions, and parent-of-origin effects. Genet Epidemiol (2004) 3.39
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet (2006) 3.13
Gene and pathway-based second-wave analysis of genome-wide association studies. Eur J Hum Genet (2010) 3.03
Multiple roles of phosphoinositide-specific phospholipase C isozymes. BMB Rep (2008) 2.90
Failure to replicate a genetic association may provide important clues about genetic architecture. PLoS One (2009) 2.72
Using genome-wide pathway analysis to unravel the etiology of complex diseases. Genet Epidemiol (2009) 2.72
Biofilter: a knowledge-integration system for the multi-locus analysis of genome-wide association studies. Pac Symp Biocomput (2009) 2.26
The SNP ratio test: pathway analysis of genome-wide association datasets. Bioinformatics (2009) 2.03
A second major histocompatibility complex susceptibility locus for multiple sclerosis. Ann Neurol (2007) 1.99
Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur J Hum Genet (2009) 1.97
Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians. Genes Immun (2008) 1.90
Systematic biological prioritization after a genome-wide association study: an application to nicotine dependence. Bioinformatics (2008) 1.85
Phospholipase C isozymes selectively couple to specific neurotransmitter receptors. Nature (1997) 1.66
Phosphoinositide binding regulates alpha-actinin dynamics: mechanism for modulating cytoskeletal remodeling. J Biol Chem (2005) 1.38
Increase in cytosolic free calcium concentration is an intracellular messenger for the production of interleukin 2 but not for expression of the interleukin 2 receptor. J Immunol (1985) 1.31
Quantitative measurements of Ca(2+)/calmodulin binding and activation of myosin light chain kinase in cells. FEBS Lett (2004) 1.27
Anti-inflammatory properties of cholinergic up-regulation: A new role for acetylcholinesterase inhibitors. Neuropharmacology (2005) 1.08
Tissue- and cell type-specific expression of mRNAs for four types of inositol phospholipid-specific phospholipase C. Biochem Biophys Res Commun (1989) 1.04
IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D). PLoS One (2009) 1.04
Astrocytes in multiple sclerosis lack beta-2 adrenergic receptors. Neurology (1999) 1.03
Myosin II activity is required for severing-induced axon retraction in vitro. Exp Neurol (2004) 1.01
Brain-specific splicing of alpha-actinin 1 (ACTN1) mRNA. Biochem Biophys Res Commun (2002) 0.94
Variation in the IL7RA and IL2RA genes in German multiple sclerosis patients. J Autoimmun (2009) 0.90
Susceptibility genes in common complex kidney disease. Curr Opin Nephrol Hypertens (2010) 0.89
Susceptibility to glaucoma: differential comparison of the astrocyte transcriptome from glaucomatous African American and Caucasian American donors. Genome Biol (2008) 0.88
Scinderin, a Ca2+-dependent actin filament severing protein that controls cortical actin network dynamics during secretion. Neurochem Res (2000) 0.85
Myosin light chain kinase: expression in neurons and upregulation during axon regeneration. J Neurobiol (1996) 0.82
Human platelets contain scinderin, a Ca(2+)-dependent actin filament-severing protein. Thromb Haemost (1992) 0.81
A unique isoform of phospholipase Cbeta4 highly expressed in the cerebellum and eye. Biochim Biophys Acta (1999) 0.81
Clinical and molecular genetic analysis of a family with macrothrombocytopenia and early onset sensorineural hearing loss. Eur J Med Genet (2009) 0.77
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 13.80
Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science (2009) 13.45
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Characterization and propagation of uncertainty in diffusion-weighted MR imaging. Magn Reson Med (2003) 12.09
CD4+CD25high regulatory cells in human peripheral blood. J Immunol (2001) 11.25
Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci (2003) 10.44
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science (1994) 8.69
fMRI resting state networks define distinct modes of long-distance interactions in the human brain. Neuroimage (2005) 8.61
Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage (2002) 8.03
Oxygenation dependence of the transverse relaxation time of water protons in whole blood at high field. Biochim Biophys Acta (1982) 7.13
T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature (1990) 4.40
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
Dissociating pain from its anticipation in the human brain. Science (1999) 4.36
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
Changes in connectivity profiles define functionally distinct regions in human medial frontal cortex. Proc Natl Acad Sci U S A (2004) 4.19
Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature (1998) 4.10
Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol (1994) 4.07
Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA (1997) 4.00
Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. Neurology (2010) 3.98
A highly polymorphic locus very tightly linked to the Huntington's disease gene. Nature (1988) 3.90
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology (2008) 3.68
Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med (1999) 3.66
The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science (1987) 3.59
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic-locus heterogeneity. N Engl J Med (1991) 3.45
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
Effects of oral administration of type II collagen on rheumatoid arthritis. Science (1993) 3.32
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther (2012) 3.16
Localization of the Huntington's disease gene to a small segment of chromosome 4 flanked by D4S10 and the telomere. Cell (1987) 3.11
An autosomal genomic screen for autism. Collaborative linkage study of autism. Am J Med Genet (1999) 3.07
ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology (1997) 3.04
A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet (1996) 2.98
A simple method for DNA purification from peripheral blood. Anal Biochem (1988) 2.98
Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science (1993) 2.97
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology (1996) 2.94
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med (1983) 2.93
Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr (2000) 2.92
Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology (2007) 2.88
Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein. Science (1990) 2.86
Cytokine gene polymorphism in human disease: on-line databases. Genes Immun (1999) 2.86
Anatomical connectivity of the subgenual cingulate region targeted with deep brain stimulation for treatment-resistant depression. Cereb Cortex (2007) 2.83
Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder. Nature (1990) 2.80
Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA (2001) 2.79
Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol (2001) 2.75
Exacerbation of pain by anxiety is associated with activity in a hippocampal network. J Neurosci (2001) 2.68
Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr (2001) 2.67
A gene responsible for the pigment dispersion syndrome maps to chromosome 7q35-q36. Arch Ophthalmol (1997) 2.64
A DNA segment encoding two genes very tightly linked to Huntington's disease. Science (1987) 2.63
Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol (1999) 2.61
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet (2015) 2.59
The use of phenome-wide association studies (PheWAS) for exploration of novel genotype-phenotype relationships and pleiotropy discovery. Genet Epidemiol (2011) 2.54
A high-density screen for linkage in multiple sclerosis. Am J Hum Genet (2005) 2.50
Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology (2004) 2.50
EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol (2010) 2.45
Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med (1994) 2.45
The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature (1995) 2.44
Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. Neurology (2008) 2.41
Paraoxonase cluster polymorphisms are associated with sporadic ALS. Neurology (2006) 2.38
Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med (1994) 2.37
Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA (2001) 2.36
Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology (2002) 2.36
Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther (2011) 2.36
Head injury and the risk of AD in the MIRAGE study. Neurology (2000) 2.34
MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology (2010) 2.33
Risk prediction of prevalent diabetes in a Swiss population using a weighted genetic score--the CoLaus Study. Diabetologia (2009) 2.32
Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature (1987) 2.32
Late complications of immune deviation therapy in a nonhuman primate. Science (1996) 2.30
IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet (2009) 2.30
HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology (2010) 2.29
Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med (1995) 2.28
Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest (1996) 2.27
In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med (1985) 2.27
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology (2011) 2.26
Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology (2011) 2.26
The fine-scale genetic structure of the British population. Nature (2015) 2.26
Clustering of multiallele DNA markers near the Huntington's disease gene. J Clin Invest (1989) 2.25
Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology (2005) 2.24
Changes in white matter microstructure during adolescence. Neuroimage (2007) 2.22
Loss of suppressor T cells in active multiple sclerosis. Analysis with monoclonal antibodies. N Engl J Med (1980) 2.21
Metabolic recovery after exercise and the assessment of mitochondrial function in vivo in human skeletal muscle by means of 31P NMR. Magn Reson Med (1984) 2.21
Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology (1998) 2.17
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
A novel method to identify gene-gene effects in nuclear families: the MDR-PDT. Genet Epidemiol (2006) 2.17
Neonatal pulmonary hypertension--urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function. N Engl J Med (2001) 2.16
Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology (2012) 2.16
Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis. Ann Neurol (2012) 2.15
Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology (2006) 2.10
Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA (2000) 2.08